What's in Prime Gene Therapeutics Co., Ltd.'s pipeline?

Prime Gene Therapeutics Co., Ltd. has 5 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with Prime Gene Therapeutics Co., Ltd.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/prime-gene-therapeutics-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Prime Gene Therapeutics Co., Ltd. — Portfolio Competitive Intelligence Brief

Prime Gene Therapeutics Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
PG-011Gel	PG-011Gel	phase 3			Genetics
Placebo (twice daily)	Placebo (twice daily)	phase 3

Therapeutic area mix

Genetics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Prime Gene Therapeutics Co., Ltd.:

Cite this brief

Drug Landscape (2026). Prime Gene Therapeutics Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prime-gene-therapeutics-co-ltd. Accessed 2026-05-16.